Do's and Dont's for Orphan Drug Support Programs: Getting personal with rare disease patients

December 13, 2016

The commercialization of a rare disease drug often comes with complex challenges and subsequent risks from development through post-launch.
by Nancy Pilcher, RN, Director of Business Development

Ensuring success takes understanding and improving every step of the patient's treatment journey. AmerisourceBergen's patient-centric approach and experience in the orphan drug market has identified best practices to help partners successfully commercialize their product.

Explore the expertise and solutions we've used to expand access and commercialize more than 100 rare disease treatments at ItTakesAmerisourceBergen.com.